In contrast, other studies also reported no significant prognostic effect of DNMT3A mutations in AML patients with intermediate risk group [27] and in low risk (NPM1 mutated but FLT3 ITD unmutated) NK AML patients [24]. The gene discussed is FLT3; the disease is acute myeloid leukemia.